Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Prostate cancer Stories

2013-12-09 12:27:39

However, the Majority of Surveyed Urologists Have Not Yet Prescribed Xtandi for This Patient Population, According to a New Report from BioTrends Research Group EXTON, Pa., Dec. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at 12 months following the U.S. launch of Medivation/Astellas Pharma's Xtandi for docetaxel-pretreated metastatic castrate-resistant prostate cancer...

2013-12-08 08:22:23

Siltuximab regulatory filing granted priority review by the United States Food and Drug Administration RARITAN, N.J., Dec. 8, 2013 /PRNewswire/ -- Janssen Research & Development, LLC ("Janssen") today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care (BSC), exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in...

2013-12-06 16:23:33

HOUSTON, Dec. 6, 2013 /PRNewswire/ -- C4 Imaging LLC is pleased to announce U.S. Food and Drug Administration 510(k) clearance of its first product, the Sirius(TM) MRI Marker. The novel Positive-Signal MRI Marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance (MR) imaging procedure. Brachytherapy, or radioactive seed implantation, is a standard option for the...

2013-12-06 15:01:22

Researchers at Vanderbilt University Medical Center and the University of Alberta in Canada have identified a biomarker for a cellular switch that accurately predicts which prostate cancer patients are likely to have their cancer recur or spread. The study, posted online recently in advance of publication in Cancer Research, was led by co-investigators Andries Zijlstra, Ph.D., assistant professor of Pathology, Microbiology and Immunology and Cancer Biology at Vanderbilt, and John Lewis,...

2013-12-06 04:20:49

LONDON, Dec. 6, 2013 /PRNewswire/ -- Edison Investment Research's report, An intriguing PROSPECT, examines the long-term investment case for Bavarian Nordic, which rests on key value driver Prostvac, its Phase III prostate cancer vaccine. Prostvac is well positioned to succeed where Provenge, the only approved prostate cancer vaccine, has so far failed. Final data from the pivotal Phase III PROSPECT trial are not due until 2016 but with enrolment on track to complete in H114, there...

2013-12-05 14:20:59

Study findings published in Cancer Prevention Research underscore viability of simulation modeling to stratify patients by disease risk to better focus resources where most beneficial Archimedes Inc., a healthcare modeling and analytics company, today announced results of a simulated clinical trial which found that the seven single-nucleotide polymorphisms (7SNP) genetic test for breast cancer was most cost effective when used to guide MRI screenings for patients found to have an...

Active Component Of Grape Seed Extract Causes Death In Cancer Cells
2013-12-05 14:49:44

University of Colorado Cancer Center A University of Colorado Cancer Center study published online ahead of print in the journal Nutrition and Cancer describes the laboratory synthesis of the most active component of grape seed extract, B2G2, and shows this synthesized compound induces the cell death known as apoptosis in prostate cancer cells while leaving healthy cells unharmed. “We’ve shown similar anti-cancer activity in the past with grape seed extract (GSE), but now we know...

2013-12-05 12:29:29

A REAL OPTION FOR STANDARD THERAPY-RESISTANT CANCERS SCOTTSDALE, Ariz., Dec. 5, 2013 /PRNewswire/ -- In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes. To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers...

2013-12-05 10:31:04

The retinoblastoma (Rb) protein plays a critical role in suppressing the multi-step process of cell migration through the bloodstream, lymphovascular invasion and the metastasis of an aggressive type of breast cancer to the lung, researchers at the University of Cincinnati (UC) Cancer Institute, the Cincinnati Cancer Center (CCC) and the UC Brain Tumor Center have found. The findings of Rb's role at multiple points in the disease process point to a potential new therapeutic target in...

2013-12-05 08:30:07

Presentation by CEO Linda Powers To Be Webcast Live BETHESDA, Md., Dec. 5, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that CEO Linda F. Powers will present at the Oppenheimer 24th Annual Healthcare Conference. The Conference will take place on December 10(th) and 11(th) at the Crowne Plaza Hotel in New York City. (Logo:...